Indapta is Frohlich’s first experience as a CEO. Named to the post in February 2022, he says that, so far, it’s been a very gratifying experience. One of the aspects that Frohlich enjoys the most is ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich is a medical oncologist and brings more than 25 ...

Rigel Appoints Mark W. Frohlich, M.D. to Board of ... IRAK1/4 and IDH1 inhibitor programs have a significant potential to benefit patients with lower-risk myelodysplastic syndrome and ...